Document is current
Any future updates will be listed below
-
Authors
Parry, Narissa http://orcid.org/0000-0001-9155-4866
Wheadon, Helen http://orcid.org/0000-0001-9902-3170
Copland, Mhairi http://orcid.org/0000-0002-7655-016X
-
Funding
Funding for this research was provided by:
University of Glasgow
Wellcome Trust (204820/Z/16/Z)
Novartis
Bristol-Myers Squibb
Takeda Pharmaceutical Company
Cyclacel Pharmaceuticals Inc., Berkeley Heights, New Jersey, United States
- License Information
-
More Information
Article History
Received: 29 September 2020
Revised: 29 January 2021
Accepted: 1 February 2021
First Online: 26 February 2021
Ethics approval and consent to participate
: This work required no ethical approval.
: M.C. has received research funding from Novartis, Bristol-Myers Squibb, Cyclacel and Takeda/Incyte, is/has been an advisory board member for Bristol-Myers Squibb, Novartis, Incyte, Daiichi Sankyo, and Pfizer and has received honoraria from Astellas, Bristol-Myers Squibb, Novartis, Incyte, Pfizer and Gilead. N.P. and H.W. have no conflicts-of-interest to declare.
